Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,851,960
  • Shares Outstanding, K 215,552
  • Annual Sales, $ 606,420 K
  • Annual Income, $ -1,277 M
  • EBIT $ -1,241 M
  • EBITDA $ -1,215 M
  • 60-Month Beta 1.13
  • Price/Sales 49.81
  • Price/Cash Flow N/A
  • Price/Book 40.44

Options Overview Details

View History
  • Implied Volatility 51.97% (-0.43%)
  • Historical Volatility 39.43%
  • IV Percentile 57%
  • IV Rank 31.44%
  • IV High 92.41% on 04/10/25
  • IV Low 33.42% on 09/11/25
  • Expected Move (DTE 10) 8.96 (6.23%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 186
  • Volume Avg (30-Day) 2,266
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 49,285
  • Open Int (30-Day) 52,682
  • Expected Range 134.89 to 152.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.00
  • Number of Estimates 8
  • High Estimate -0.68
  • Low Estimate -1.32
  • Prior Year -1.42
  • Growth Rate Est. (year over year) +29.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.82 +3.62%
on 03/09/26
167.37 -14.05%
on 02/20/26
-4.70 (-3.16%)
since 02/10/26
3-Month
138.82 +3.62%
on 03/09/26
205.23 -29.91%
on 12/17/25
-46.00 (-24.23%)
since 12/10/25
52-Week
60.40 +138.16%
on 04/09/25
212.75 -32.39%
on 12/02/25
+70.78 (+96.87%)
since 03/10/25

Most Recent Stories

More News
Stocks Decline Amid AI Fears and Geopolitical Risks

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.41%. March...

DE : 592.72 (-1.13%)
TAP : 45.87 (-0.30%)
TXN : 197.46 (+0.64%)
$IUXX : 24,956.47 (-0.04%)
ASML : 1,383.40 (+1.91%)
ZNM26 : 112-095 (-0.14%)
OXY : 53.12 (-3.45%)
ESH26 : 6,784.50 (-0.04%)
QCOM : 135.20 (-2.11%)
STX : 384.29 (+2.66%)
WDC : 266.22 (+1.59%)
W : 74.83 (-1.18%)
Insmed: Q4 Earnings Snapshot

Insmed: Q4 Earnings Snapshot

INSM : 143.85 (+0.50%)
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

—Company Expects Full-Year 2026 BRINSUPRI ® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE ®  (amikacin liposome inhalation suspension)...

INSM : 143.85 (+0.50%)
Insmed To Present at March 2026 Investor Conferences

BRIDGEWATER, N.J. , Feb. 13, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 143.85 (+0.50%)
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

BRIDGEWATER, N.J. , Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 143.85 (+0.50%)
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary...

INSM : 143.85 (+0.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised...

INSM : 143.85 (+0.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised...

INSM : 143.85 (+0.50%)
S&P 500 Rallies to a New Record High on US Economic Optimism

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.02%. March E-mini S&P...

AMAT : 345.88 (+2.05%)
MAT : 16.04 (+0.19%)
NRG : 155.15 (-0.17%)
AVGO : 342.58 (-0.92%)
SNDK : 618.89 (+5.12%)
DHI : 145.28 (-1.63%)
BLDR : 93.68 (-1.34%)
$IUXX : 24,956.47 (-0.04%)
ASML : 1,383.40 (+1.91%)
ZNM26 : 112-095 (-0.14%)
KBH : 55.92 (-2.51%)
ESH26 : 6,784.50 (-0.04%)
Stocks Push Higher on US Economic Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.59%. March E-mini S&P futures (ESH26...

AMAT : 345.88 (+2.05%)
MAT : 16.04 (+0.19%)
NRG : 155.15 (-0.17%)
AVGO : 342.58 (-0.92%)
DHI : 145.28 (-1.63%)
SNDK : 618.89 (+5.12%)
BLDR : 93.68 (-1.34%)
$IUXX : 24,956.47 (-0.04%)
ASML : 1,383.40 (+1.91%)
ZNM26 : 112-095 (-0.14%)
KBH : 55.92 (-2.51%)
OLN : 23.53 (-1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 148.18
2nd Resistance Point 146.91
1st Resistance Point 145.38
Last Price 143.85
1st Support Level 142.58
2nd Support Level 141.31
3rd Support Level 139.78

See More

52-Week High 212.75
Fibonacci 61.8% 154.55
Last Price 143.85
Fibonacci 50% 136.57
Fibonacci 38.2% 118.60
52-Week Low 60.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar